Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Eloxx Pharmaceuticals Inc (ELOX) has shared an update.
Eloxx Pharmaceuticals has initiated a stock option repricing for their CEO’s eligible options under the 2018 Equity Incentive Plan, reducing the exercise price to $0.90, aligning with the closing stock price on March 25, 2024. This move affects both vested and unvested options, significantly lowering the weighted average exercise price from $37.47 for nearly 200,000 shares owned by CEO Sumit Aggarwal, potentially making it more attractive for investment and retention purposes.
See more insights into ELOX stock on TipRanks’ Stock Analysis page.
